Monograph Details
|
|
Neoplasms
> Alkylating agents
|
|
MUSTARGEN |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Nitrogen mustard. |
| Generic Name |
|
Mechlorethamine HCl 10mg/vial; pwd for IV or intracavitary inj after reconstitution. |
| Indications |
|
Palliative treatment of Hodgkin's disease (stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, bronchogenic carcinoma. Palliative treatment of metastatic carcinoma resulting in effusion. |
| Children |
|
See literature. |
| Adults |
|
By IV infusion, per therapeutic course: 0.4mg/kg (lean body weight) as single dose or in divided doses of 0.1–0.2mg/kg per day. See literature for intracavitary (eg, intrapleural) administration. Do not exceed recommended dose. Repeat course only after hematological recovery (eg, every 3 weeks). |
| Contraindications |
|
Infectious diseases. |
| Precautions |
|
Drug is highly toxic; verify potential benefits outweigh risks; avoid inadvertent contact with powder or vapor. Do not use if foci of acute and chronic suppurative inflammation are present. Ensure adequate hydration. Avoid extravasation. Chronic lymphatic leukemia. Bone marrow suppression. Previous X-ray, cytotoxic chemotherapy. Infection. Hemorrhagic tendency. Monitor renal, hepatic and bone marrow function. Elderly. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended. |
| Adverse Reactions |
|
Bone marrow suppression, hyperheparinemia, GI upset (may be severe), anorexia, weakness, thrombosis, thrombophlebitis, hypersensitivity, jaundice, alopecia, vertigo, auditory disturbances, hemolytic anemia, skin reactions, infection, amyloidosis, hyperuricemia, gonad damage. |
| How Supplied |
|
Vials—4 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
